Summary & Overview
HCPCS J9208: Ifosfamide Injection, 1 Gram
HCPCS Level II code J9208 denotes a 1-gram injection of ifosfamide, an antineoplastic agent used in systemic chemotherapy. Nationally, accurate coding of antineoplastic injections matters for clinical tracking, payer reimbursement, and claims integrity across hospital outpatient departments and infusion centers. This code identifies the specific drug and unit of measure, which supports dosing reconciliation, inventory control, and payer billing rules.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and common billing modifiers used with antineoplastic injections. The publication outlines benchmarks and policy-relevant considerations related to drug unit reporting, billing unit conversion, and site-of-service impacts on coverage and payment. It also highlights operational aspects—such as infusion-center billing flows and hospital outpatient reporting—that affect claim processing for chemotherapy agents.
Where specific input fields were not provided, the publication indicates that structured data elements are not available in the input. The content is intended for a national audience of billing professionals, clinical coders, and policy analysts seeking a clear summary of HCPCS Level II code J9208 and its role in chemotherapy billing workflows.
Billing Code Overview
HCPCS Level II code J9208 represents an injection of ifosfamide, with the billing unit defined as 1 gram. This code is used to report administration of the chemotherapeutic agent ifosfamide for systemic cancer therapy.
Service Type: Chemotherapy administration / Antineoplastic injection
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving intravenous ifosfamide chemotherapy for a solid tumor such as soft tissue sarcoma or testicular cancer. The medication billed as J9208 (ifosfamide, 1 gram) is prepared by the outpatient oncology infusion center pharmacy or hospital inpatient pharmacy and administered by oncology nursing under an oncologist’s orders. The clinical workflow includes: pre-chemotherapy assessment (vital signs, laboratory review with focus on renal function and complete blood count), premedication as indicated (antiemetics and mesna for uroprotection when required), peripheral IV or central venous access verification, infusion of ifosfamide diluted per institutional protocol with appropriate hydration, continuous monitoring for neurotoxicity, nephrotoxicity, and hemorrhagic cystitis, and post-infusion observation with discharge instructions. Documentation includes chemotherapy order with regimen/weight-based dosing, lot numbers and vial/ampule usage tied to J9208 units, administration start/stop times, any modifier use (for example, reasons for discontinued administration), and related supportive care medications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-use vial of ifosfamide is wasted after opening and payer requires reporting of discarded drug. |